Chronic Active Epstein-Barr Virus (EBV) Infection Controlled by Allogeneic Stem Cell Transplantation and EBV-Specific T Cells.

Abstract

We report sustained remission of chronic active Epstein-Barr virus (EBV) infection in a 27-year-old female patient treated with third-party EBV-specific T cells followed by allogeneic hematopoietic stem cell transplantation (HSCT). The viremia cleared after administration of anti-T-lymphocyte globulin for graft-versus-host disease (GvHD) prophylaxis. Subsequent expansion of EBV-infected host T cells was controlled by transfusion of donor-derived EBV-specific T cells.

• Authors: Elisabeth Meedt, Daniela Weber, Agnes Bonifacius, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Susanne Delecluse, Henri-Jacques Delecluse, Myriam Lorenz, Klaus Schwarz, Stefan T Meedt, Jan Braess, Wolfgang Herr, Ernst Holler, Matthias Edinger, Daniel Wolff
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 76 Issue 12 Pg. 2200-2202 (06 16 2023) ISSN: 1537-6591 [Electronic] United States
• PMID: 36883586 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].

Topics

• Female
• Humans
• Adult
• Epstein-Barr Virus Infections (therapy)
• Herpesvirus 4, Human
• Transplantation, Homologous (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• T-Lymphocytes
• Graft vs Host Disease